MA27929A1 - Utilisation de calcitonine pour le traitement de l'osteoarthrite - Google Patents

Utilisation de calcitonine pour le traitement de l'osteoarthrite

Info

Publication number
MA27929A1
MA27929A1 MA28746A MA28746A MA27929A1 MA 27929 A1 MA27929 A1 MA 27929A1 MA 28746 A MA28746 A MA 28746A MA 28746 A MA28746 A MA 28746A MA 27929 A1 MA27929 A1 MA 27929A1
Authority
MA
Morocco
Prior art keywords
osteoarthritis
calcitonin
treatment
mammals
treating
Prior art date
Application number
MA28746A
Other languages
English (en)
Inventor
Moise Azria
Claus Christiansen
Simon David Bateman
Shoufeng Li
Original Assignee
Novartis Ag
Nordic Bioscience As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27929(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Nordic Bioscience As filed Critical Novartis Ag
Publication of MA27929A1 publication Critical patent/MA27929A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Nouvelle utilisation de la calcitonine pour le traitement de l'ostéoarthrite et méthodes de traitement et / ou de prévention de l'ostéoarthrite chez des mammifères, en particulier des êtres humaines.
MA28746A 2003-07-23 2006-01-23 Utilisation de calcitonine pour le traitement de l'osteoarthrite MA27929A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48940003P 2003-07-23 2003-07-23

Publications (1)

Publication Number Publication Date
MA27929A1 true MA27929A1 (fr) 2006-06-01

Family

ID=34135096

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28746A MA27929A1 (fr) 2003-07-23 2006-01-23 Utilisation de calcitonine pour le traitement de l'osteoarthrite

Country Status (23)

Country Link
US (3) US7749954B2 (fr)
EP (2) EP1651249B1 (fr)
JP (2) JP4716987B2 (fr)
KR (1) KR101070036B1 (fr)
CN (1) CN1856321B (fr)
AU (2) AU2004262906B2 (fr)
BR (1) BRPI0412265A (fr)
CA (1) CA2532565C (fr)
ES (2) ES2398237T3 (fr)
HK (2) HK1089935A1 (fr)
IL (2) IL173002A (fr)
IS (1) IS8316A (fr)
MA (1) MA27929A1 (fr)
MX (1) MXPA06000807A (fr)
NO (1) NO330867B1 (fr)
NZ (1) NZ544645A (fr)
PL (2) PL2316473T3 (fr)
PT (2) PT1651249E (fr)
RU (1) RU2368390C2 (fr)
TN (1) TNSN06022A1 (fr)
TW (1) TWI343816B (fr)
WO (1) WO2005014031A1 (fr)
ZA (1) ZA200600373B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005080A (es) * 2004-05-27 2005-11-30 Aspid S A De C V Una composicion moduladora de la inflamacion articular cronica a base de colagena-polivinilpirrolidona.
WO2007035718A2 (fr) 2005-09-19 2007-03-29 Emisphere Technologies, Inc. Formes cristallines du sel disodique de l'acide n-(5-chlorosalicyloyl)-8-aminocaprylique
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
JP2009515993A (ja) 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト 医薬組成物
AU2007289344B2 (en) 2006-08-31 2011-04-14 Novartis Ag Pharmaceutical compositions comprising hGH for oral delivery
PT2131810E (pt) * 2007-03-02 2011-08-03 Novartis Ag Administração oral de uma calcitonina
WO2009019307A2 (fr) * 2007-08-09 2009-02-12 Novartis Ag Compositions à base de calcitonine orale et leurs applications
BRPI0817396C8 (pt) 2007-11-02 2021-05-25 Emisphere Tech Inc composição farmacêutica para tratar deficiência de vitamina b¹²
NZ591497A (en) * 2008-08-18 2012-11-30 Entera Bio Ltd A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment
EP2405934B1 (fr) * 2009-03-12 2014-03-26 Nordic Bioscience A/S Traitement du diabète et du syndrome métabolique
WO2011067283A1 (fr) * 2009-12-01 2011-06-09 Novo Nordisk A/S Nouvelles peptidyl a-hydroxyglycine a-amide lyases
WO2012040364A1 (fr) * 2010-09-21 2012-03-29 Unigene Laboratories Inc. Produits et thérapies à base de calcitonine pour traiter des maladies inflammatoires ou dégénératives
JP6170933B2 (ja) 2011-11-02 2017-07-26 キーバイオサイエンス・アクチエンゲゼルシャフト ペプチドの使用
HUE039105T2 (hu) 2011-11-02 2018-12-28 Keybioscience Ag Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
US11549098B2 (en) * 2012-03-16 2023-01-10 Fertility Innovations Limited Processing of sperm cells
DK3068796T3 (en) 2013-11-14 2018-03-05 Keybioscience Ag CALCITONIN MIMETICS FOR THE TREATMENT OF DISEASES AND DISORDERS
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190036903A (ko) 2017-09-28 2019-04-05 (주)휴럼 리트세노라이드를 유효성분으로 하는 염증과 골관절염에 대한 예방 및 치료용 약학 조성물
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
CN108586601B (zh) * 2018-05-14 2021-07-27 四川大学 一种骨靶向性鲑鱼降钙素及其制备方法
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
CN117714967A (zh) 2020-03-02 2024-03-15 奇跃公司 沉浸式音频平台

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US608618A (en) 1898-08-09 Thomas millen
HU203204B (en) 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
JP3501471B2 (ja) * 1992-06-15 2004-03-02 旭化成ファーマ株式会社 カルシトニン類の安定化組成物および安定化法
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
GB9623205D0 (en) * 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE60017888T2 (de) * 1999-04-05 2006-01-19 Emisphere Technologies, Inc. Dinatrium-salze, monohydrate und ethanol-solvate
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US20020012459A1 (en) * 2000-06-22 2002-01-31 Chips Brain Co. Ltd. Method and apparatus for detecting stereo disparity in sequential parallel processing mode
EP1313699B1 (fr) 2000-08-29 2010-03-10 Biocon Limited Derives 5-asa ayant une activite anti-inflammatoire et antibiotique, procedes de traitement de maladies a l'aide de ces derniers
PL365643A1 (en) 2000-10-25 2005-01-10 Smithkline Beecham Corporation Calcilytic compounds
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
CA2453646C (fr) 2001-08-17 2008-09-30 Novartis Ag 5-cnac utilise en tant qu'agent d'administration par voie orale pour des fragments d'hormone parathyroidienne

Also Published As

Publication number Publication date
PL1651249T3 (pl) 2013-04-30
IL227988A (en) 2016-10-31
US8765675B2 (en) 2014-07-01
ES2436152T3 (es) 2013-12-27
TNSN06022A1 (en) 2007-10-03
NO330867B1 (no) 2011-08-01
US7749954B2 (en) 2010-07-06
WO2005014031A1 (fr) 2005-02-17
ES2398237T3 (es) 2013-03-14
NZ544645A (en) 2009-04-30
RU2368390C2 (ru) 2009-09-27
ZA200600373B (en) 2007-01-31
IS8316A (is) 2006-02-21
CA2532565A1 (fr) 2005-02-17
HK1152229A1 (en) 2012-02-24
NO20060890L (no) 2006-04-24
JP4716987B2 (ja) 2011-07-06
RU2006105479A (ru) 2007-09-10
TWI343816B (en) 2011-06-21
IL173002A0 (en) 2006-06-11
JP2006528152A (ja) 2006-12-14
CN1856321B (zh) 2012-10-03
EP1651249B1 (fr) 2012-09-12
AU2004262906A1 (en) 2005-02-17
KR101070036B1 (ko) 2011-10-04
TW200518769A (en) 2005-06-16
BRPI0412265A (pt) 2006-09-05
PL2316473T3 (pl) 2014-05-30
HK1089935A1 (en) 2006-12-15
US20140271735A1 (en) 2014-09-18
IL173002A (en) 2013-09-30
AU2008202879A1 (en) 2008-07-24
IL227988A0 (en) 2013-09-30
PT2316473E (pt) 2013-09-20
CA2532565C (fr) 2012-05-08
US20060194722A1 (en) 2006-08-31
US20100278881A1 (en) 2010-11-04
PT1651249E (pt) 2012-12-21
KR20060034298A (ko) 2006-04-21
EP2316473A1 (fr) 2011-05-04
EP1651249A1 (fr) 2006-05-03
JP2011121987A (ja) 2011-06-23
CN1856321A (zh) 2006-11-01
AU2004262906B2 (en) 2008-04-03
EP2316473B1 (fr) 2013-08-21
MXPA06000807A (es) 2006-08-23
AU2008202879B2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
DE50309853D1 (de) Lineare polyamino- und/oder polyammonium-polysiloxancopolymere ii
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
BR0316000A (pt) Copolìmeros lineares de poliamino- e/ou poliamÈnio-polissiloxano i
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
ATE254461T1 (de) Behandlung von augenschmerzen
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
ATE457998T1 (de) Abgeschwächte mikroorganismen für die behandlung von infektionen
FR2834459B1 (fr) Agent microbicide et composition de traitement cosmetique le contenant
FR2825273B1 (fr) Composition pour le traitement des signes cutanes du vieillissement
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
TR200200278T2 (tr) Kalsilitik bileşimler
ATE347888T1 (de) Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
FR2938429B1 (fr) Utilisation cosmetique de microorganisme(s) pour le traitement des desordres du cuir chevelu
DZ3449A1 (fr) Composition sous forme d'emulsion appropriee pour le traitement de l'hyperhidrose et/ou bromhidrose plantaire.
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
BRPI0411382A (pt) derivados de 2-aminobenzoil
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
FR2855056B1 (fr) Medicament notamment pour le traitement de la drepanocytose ou du sida
BR0211533A (pt) Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas